{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:19Z","timestamp":1785186499402,"version":"3.55.0"},"reference-count":31,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9,1]]},"DOI":"10.1210\/jc.2007-2658","type":"journal-article","created":{"date-parts":[[2008,6,18]],"date-time":"2008-06-18T00:45:06Z","timestamp":1213749906000},"page":"3348-3356","source":"Crossref","is-referenced-by-count":110,"title":["Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma"],"prefix":"10.1210","volume":"93","author":[{"given":"Marleen","family":"Kars","sequence":"first","affiliation":[{"name":"Departments of Endocrinology and Metabolic Diseases (M.K., J.W.A.S., J.A.R., A.M.P.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[{"name":"Cardiology (V.D., E.R.H., J.J.B.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Cardiology (V.D., E.R.H., J.J.B.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (R.A.F.), Section of Endocrinology, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. A.","family":"Smit","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology and Metabolic Diseases (M.K., J.W.A.S., J.A.R., A.M.P.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A.","family":"Romijn","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology and Metabolic Diseases (M.K., J.W.A.S., J.A.R., A.M.P.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.","family":"Bax","sequence":"additional","affiliation":[{"name":"Cardiology (V.D., E.R.H., J.J.B.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[{"name":"Departments of Endocrinology and Metabolic Diseases (M.K., J.W.A.S., J.A.R., A.M.P.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113572752700_R1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide.","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041113572752700_R2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson\u2019s disease treated with high-dose pergolide.","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041113572752700_R3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease.","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113572752700_R4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041113572752700_R5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041113572752700_R6","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","article-title":"Fibrotic valvular heart disease subsequent to bromocriptine treatment.","volume":"10","author":"Serratrice","year":"2002","journal-title":"Cardiol Rev"},{"key":"key\n\t\t\t\t2019041113572752700_R7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041113572752700_R8","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation.","volume":"353","author":"Pinero","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation.","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease.","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly.","volume":"89","author":"Pereira","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113572752700_R12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041113572752700_R13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"key\n\t\t\t\t2019041113572752700_R14","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1161\/CIRCULATIONAHA.106.176857","article-title":"guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons","volume":"114","author":"Bonow","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113572752700_R15","first-page":"230","article-title":"Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.","volume":"28","author":"Vahanian","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041113572752700_R16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","article-title":"Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study).","volume":"83","author":"Singh","year":"1999","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t2019041113572752700_R18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","article-title":"Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.","volume":"16","author":"Van der Klaauw","year":"2006","journal-title":"Growth Horm IGF Res"},{"key":"key\n\t\t\t\t2019041113572752700_R19","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","article-title":"Thyroid disease and the heart.","volume":"116","author":"Klein","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113572752700_R20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1210\/er.2003-0033","article-title":"Thyroid hormone action in the heart.","volume":"26","author":"Kahaly","year":"2005","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113572752700_R21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7326\/0003-4819-117-1-50","article-title":"Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations.","volume":"117","author":"Redfield","year":"1992","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113572752700_R22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R23","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113572752700_R24","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","article-title":"Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.","volume":"101","author":"Jollis","year":"2000","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113572752700_R25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041113572752700_R26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0025-6196(11)62328-8","article-title":"Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years.","volume":"77","author":"Simula","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t2019041113572752700_R27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejphar.2005.03.010","article-title":"Agonism at 5-HT2B receptors is not a class effect of the ergolines.","volume":"513","author":"Jahnichen","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019041113572752700_R28","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019041113572752700_R29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease.","volume":"348","author":"Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113572752700_R30","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(05)66461-6","article-title":"Multiplicity in randomised trials I: endpoints and treatments.","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113572752700_R31","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","article-title":"Multiplicity in randomised trials II: subgroup and interim analyses.","volume":"365","author":"Schulz","year":"2005","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/9\/3348\/9057668\/jcem3348.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T04:29:06Z","timestamp":1557635346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/9\/3348\/2596605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2658","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,1]]}}}